TICKERNERD
Menu
TMOTMOHealthcare · Diagnostics & Research

TMO Stock Forecast: Thermo Fisher Scientific, Inc. Price Predictions for 2026-2027

Last close, 9 Sept 2026
$606
+0.44% on the day

The 29 Wall Street analysts covering Thermo Fisher Scientific, Inc. hold a median 12-month price target of $650 — +7.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 8 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$223.0B
Ticker Nerd rank
82 / 100
Median analyst target
$650
Analysts covering
29
Revenue$12.0B+10.5% y/y
Operating income$2.2B
Net income$1.7B
Free cash flow$1.7B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.9%
1M
+2.0%
YTD
+4.7%
1Y
+26.0%
From 52W high
−5.1%
From 52W low
+38.3%
$438
$638
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TMO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Thermo Fisher Scientific, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Sept 2026
82 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Value
90
Revisions
86
Momentum
80
Quality
79
Growth
64
Issuance
50
Accruals
35
Size
1

Volatility (96): The share price has been relatively steady.

Accruals (35): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TMO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TMO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$400$500$600$700$800Oct 25Jan 26Apr 26Jul 26TMOHigh $750Median $650Low $520

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says29 analysts
23 Buy5 Hold1 Sell
Low $520Median $650High $750

The green dot is the last close — the median target sits +7.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
9 Sept 2026UBSAssumesBuy$540 → $730
3 Sept 2026CLSAInitiatesOutperform$748
27 July 2026Morgan StanleyMaintainsOverweight—
27 July 2026Morgan StanleyMaintainsOverweight$620 → $650
27 July 2026Piper SandlerMaintainsNeutral—
27 July 2026Piper SandlerMaintainsNeutral$510 → $600
24 July 2026BarclaysMaintainsOverweight$625 → $650
24 July 2026BarclaysMaintainsOverweight—
24 July 2026RBC CapitalMaintainsSector Perform$490 → $580
24 July 2026RBC CapitalMaintainsSector Perform—
6 July 2026Evercore ISI GroupMaintainsOutperform—
6 July 2026Evercore ISI GroupMaintainsOutperform$575 → $570
26 June 2026BernsteinReinstatesMarket Perform$520
11 June 2026Piper SandlerInitiatesNeutral—
3 June 2026HSBCDowngradeHold—
2 June 2026Wolfe ResearchAssumesOutperform$535
8 May 2026Wells FargoMaintainsOverweight—
24 Apr 2026BairdMaintainsOutperform—
24 Apr 2026StifelMaintainsBuy—
14 Apr 2026BarclaysMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TMO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TMO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 9 Sept 2026, Thermo Fisher Scientific, Inc. returned +26.0% against +18.5% for the S&P 500, dividends included.

TMO vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Oct 25Jan 26Apr 26Jul 26TMOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TMO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+1.1%
Analysts raising
24
Analysts cutting
0
Fundamentals

Thermo Fisher Scientific, Inc. (TMO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
32.6×

Cheaper than 23% of US stocks

Price / sales
4.8×

Cheaper than 25% of US stocks

Price / book
4.3×

Cheaper than 24% of US stocks

EV / EBITDA
22.3×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
10.5%

Higher than 53% of US stocks

Earnings growth (YoY)
7.4%

Higher than 44% of US stocks

Gross margin
40.7%

Higher than 51% of US stocks

Operating margin
18.8%

Higher than 77% of US stocks

Net margin
15.0%

Higher than 77% of US stocks

Returns & dividend
Return on equity
13.5%

Higher than 72% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
0.3%

Higher than 5% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Thermo Fisher Scientific, Inc. (TMO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Thermo Fisher Scientific, Inc. has a market value of $223.0B and an enterprise value of $261.6B.

  • Revenue in the twelve months to 30 June 2026: $46.3B. The latest quarter grew 10.5% year on year.

  • Net income over the same four quarters: $7.0B, a 15.1% net margin.

  • Diluted earnings per share, trailing twelve months: $18.59.

  • Free cash flow in the twelve months to 30 June 2026: $7.3B.

  • Thermo Fisher Scientific, Inc. spent $5.0B on share buybacks and $662.0M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 369.7M.

  • Trailing P/E: 32.6×; forward P/E: 22.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.31%, paying out 10% of earnings.

  • Thermo Fisher Scientific, Inc. employs 125,000 people — $371K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 9 Sept 2026

Data provided by Twelve Data

Peers

TMO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
TMOThermo Fisher Scientific, Inc.$223.0B
82
DHRDanaher Corp.$145.0B
73
NTRANatera, Inc.$44.7B
81
IQVIQVIA Holdings, Inc.$42.7B
91
AAgilent Technologies, Inc.$41.6B
87
IDXXIDEXX Laboratories, Inc.$41.5B
92
WATWaters Corp.$39.5B
52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Thermo Fisher Scientific, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TMO news & analysis

Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus

Zacks Investment Research · 8 Sept 2026neutral

Zacks Research highlighted standout gains from its key stock portfolios and spotlighted Oportun Financial, Uranium Royalty, and Amgen in its latest market commentary.

Why it matters — The item does not mention Thermo Fisher Scientific, so TMO watchers can note the coverage centers on other companies and portfolio performance rather than developments at TMO itself.

Should You Continue to Hold TMO Stock in Your Portfolio?

Zacks Investment Research · 4 Sept 2026neutral

The article examines whether investors should continue holding TMO stock, noting that Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, while macro risks and competition remain ongoing concerns.

Why it matters — TMO watchers would care because it highlights both the growth potential from acquisitions and the lingering macroeconomic and competitive risks facing the company.

Why Moderna's Cancer Vaccine Matters to Investors

ETF Trends · 2 Sept 2026neutral

The article discusses the shift in healthcare toward individualized therapies, highlighted by Moderna's cancer vaccine. It describes a move away from mass-produced, one-size-fits-all treatments toward personalized medicine designed to improve effectiveness and reduce adverse side effects.

Why it matters — Thermo Fisher Scientific watchers would care because a broader industry shift toward individualized therapies suggests growing demand for the specialized tools, reagents, and technologies used in personalized medicine development.

Thermo Fisher Scientific Launches Multiskan™ Ease Absorbance Microplate Reader to Help Simplify Protein, Cell and Microbial Analysis

Business Wire · 2 Sept 2026positive

Thermo Fisher Scientific announced the launch of the Thermo Scientific Multiskan Ease Absorbance Microplate Reader, an instrument designed to support protein quantification, ELISAs, cell viability studies, and microbial growth monitoring with simplified operation and dependable performance for routine laboratory applications.

Why it matters — The new product launch expands Thermo Fisher's laboratory instrument portfolio, offering a solution aligned with growing laboratory demand for reliable absorbance-based analysis.

TMO Stock Could Gain Following the Launch of EMPAD G2 Detector

Zacks Investment Research · 1 Sept 2026positive

Thermo Fisher has launched the EMPAD G2 detector, which is reported to enhance 4D STEM imaging speed, sensitivity, and workflow integration, thereby strengthening its Analytical Instruments portfolio.

Why it matters — This product launch bolsters Thermo Fisher's Analytical Instruments offering, a key segment that TMO watchers track for the company's competitive position.

FAQ

Frequently asked questions about TMO stock

What is the TMO stock price forecast for 2026-2027?

The 29 Wall Street analysts covering Thermo Fisher Scientific, Inc. have a median 12-month price target of $650, with estimates ranging from $520 to $750. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TMO stock a buy right now?

Of the 29 analysts covering Thermo Fisher Scientific, Inc., 23 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 across roughly 4,600 US stocks as at 8 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TMO?

As at 8 Sept 2026, Thermo Fisher Scientific, Inc. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will TMO stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +7.3% from the last close, and Ticker Nerd's factor model ranks Thermo Fisher Scientific, Inc. 82 out of 100 as at 8 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TMO stock forecast for 2030?

No analyst covering Thermo Fisher Scientific, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TMO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $520 to $750 over the next 12 months.

How has TMO stock performed over the past year?

Thermo Fisher Scientific, Inc. returned +26.0% over the 12 months to 9 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Thermo Fisher Scientific, Inc. do?

Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services.

What is the latest news on TMO?

The most recent item we track (Zacks Investment Research, 8 Sept 2026): "Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus". Zacks Research highlighted standout gains from its key stock portfolios and spotlighted Oportun Financial, Uranium Royalty, and Amgen in its latest market commentary.

Company

About Thermo Fisher Scientific, Inc.

Thermo Fisher Scientific Inc. is a global life sciences company that provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services. Its portfolio supports scientific research, clinical testing, drug discovery, and pharmaceutical manufacturing through a broad range of instruments, reagents, consumables, software, and services. The company serves customers across pharmaceutical and biotechnology firms, hospitals, clinical diagnostic laboratories, universities, research institutions, and government agencies. Thermo Fisher Scientific Inc. operates through several business segments that address research, analysis, diagnostics, and laboratory workflow needs, making it an important supplier to healthcare, industrial, and scientific markets worldwide. Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. is recognized for its role in enabling laboratory productivity and supporting the development, testing, and production of modern therapies and diagnostics.

CEO Mr. Marc N. Casper · 125,000 employees · United States · https://www.thermofisher.com